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Identity 
Other names: Stiff-man syndrome 
Inheritance: none known 
Clinics 
Stiff-person syndrome is a rare neurological disorder 
characterized by stiffness of skeletal muscles with 
superimposed spasms. The syndrome is a putative 
autoimmune disease occurring as an idiopathic or 
paraneoplastic condition. It is often associated with 
antibodies to glutamic acid decarboxylase (GAD) or, 
less commonly, to the 128 kD synaptic protein later 
amphiphysin (AMPH) and few other autoantigens. 
Phenotype and clinics 
Diagnosis of GAD-antibody associated stiff-person 
syndrome is made according to the following criteria: 
- Prodrome of stiffness and rigidity in axial muscles,  
- Progression to include stiffness of limbs, making 
walking difficult,  
- Increased lumbar lordosis,  
- Presence of superimposed painful spasm, often 
precipitated by external stimuli (auditory stimulation 
like hand clapping),  
- Normal sensation, no paresis,  
- An EMG finding of continuous motor unit activity 
(CMUA) at rest,  
- Response to benzodiazepines including clinical 
response and reduction on CMUA,  
- High levels of GAD antibodies,  
- Other features: Less frequently, stiff-person syndrome 
is associated with antibodies to the 128 kDa synaptic 
protein amphiphysin. It is then a paraneoplastic 
condition, most often occurring with breast cancer. The 
pathogenic role of the antibodies directed against the 
128 kDa synaptic protein amphiphysin has been shown  
by transmission of disease symptoms by passive 
transfer to rats. One case of stiff-person syndrome 
associated with antibodies to the synaptic protein 
gephyrin has been described. 
  
 
Western blots of brain homogenates showing protein antigens 
recognized by serum and cerebrospinal fluid samples from 
patients 1,2 and 3, affected by stiff-man syndrome and breast 
cancer (lane 1,2 and 3) and by serum samples from control 
patients and normal subjects. The sera from the three patients 
affected by affected by stiff-man syndrome and breast cancer 
did not react with the Gad band, which was recognized by a 
human serum positive for GAD antibodies (lane 4). Lane 5, 
serum from a control patient with the stiff-man syndrome who 
did not have GAD antibodies; and lane 6 serum of a normal 
subject. A band with an apparent molecular mass of 128 kd 
was recognized by the serum samples of patient 1, 2 and 3. 
Lane 7 and 8 were both loaded with 20 µg of protein from a 
homogenate of a rat brain and were labelled with serum and 
cerebrospinal fluid, respectively, from patient 3. (Reprinted with 
permission from F. Folli et al, Autoantibodies to a 128 kd 
protein in three women with the stiff-man syndrome and breast 
cancer. N Engl J Med 1993; 328: 546-551. Copyright 1993 
Massachusetts Medical Society. All rights reserved). 
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Neoplastic risk 
GAD-antibody positive stiff-person syndrome has not
been described as a paraneoplastic condition. Most 
cases of amphiphysin antibody associated stiff-person 
syndrome are paraneoplastic. Cancers described are 
breast cancer, small-cell lung, and ovarian carcinoma. 
The one case with anti-gephyrin antibodies was 
associated with an undifferentiated carcinoma of the
mediastinum. 
Treatment 
Patients may respond to symptomatic treatment with 
benzodiazepines, and to a certain extent baclofen, 
valproic acid, tiagabine, and other drugs enhancing 
GABAergic transmission. Given the autoinmune 
pathogenesis immunosuppression, plasmapheresis, and 
high dose intravenous immunoglobulins (IVIG) seem 
to be treatments of choice. The only randomized 
controlled trial in this disorder showed that IVIG was 
an efficient treatment in GAD-antibody positive stiff-
person syndrome. In the paraneoplastic forms, removal 
of the cancer is essential. Anti-amphiphysin associated 




Anti-amphiphysin antibody titers during two series of plasma 
exchanges (filled squares: anti-amphysin titer, arrows: days of 
plasma exchange) in a patient with anti-amphiphysin 
associated stiff-person syndrome. Clinical improvement closely 
correlated with drop in titer. (Reprinted from Wessig et al, 
Neurology 2003; 61:195-198, with permission). 
Evolution 
GAD-antibody positive stiff-person syndrome is 
usually slowly progressive, but can make patients bed-
bound in the end. The paraneoplastic types are usually 
rapidly progressive and may be associated with 
encephalitis and other paraneoplastic syndromes. The 
prognosis of the neurological disorder depends on 
tumor treatment. 
Genes involved and Proteins 
GAD2 (Glutamate decarboxylase 2) 
Location: 10p12 
Note: GAD2 isthe rate limiting enzyme of GABA 
synthesis. Stiff-person syndrome with autoantibodies 
directed against GAD is associated with type 1 diabetes 
mellitus and polyendocrine autoimmune diseases, 
including Grave’s disease, hypothyroidism, Addison’ 
disease and atrophic gastritis. 
AMPH (Amphiphysin) 
Location: 7p14 
Note: AMPH is a 128 kd synaptic protein. It supports 
endocytosis at synapses by the formation of dynamin-
rings around clathrin vesicles. Stiff-person syndrome, 
with autoantibodies directed against Amphiphysin, is 
associated with breast cancer. 
GPHN (Gephyrin) 
Location: 14q24 
Note: GPHN is a postsynaptic protein needed for the 
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Photomicrographs of Sections of Rat Cerebellum and Brain Stem Stained with Serum Samples (Diluted 1:20) from Patients 1, 2, and 3 
affected by stiff-man syndrome and breast cancer, and a Control Patient affected by stiff-man syndrome with autoantibodies against 
glutamic acid decarboxilase and with Rabbit Antibodies to Synaptic-Vesicle Proteins. In Panels A through I, immunoperoxidase staining 
was used (immunoreactive areas are black), and in Panel J and Panel K, immunofluorescence staining was used (immunoreactive 
areas are white). In Panel A, a sagittal section of cerebellum stained with serum from Patient 1 shows staining of all regions containing 
synapses in the cerebellar cortex and the deep cerebellar nuclei (DCN). The dense staining of the molecular layer (ML) and the patchy 
staining of the granular layer (GL) correspond to the known distribution of synapses in the two layers. 
In Panel B, cerebellar cortex stained with serum from Patient 3 shows widespread immunoreactivity on synapses. 
In Panel C, cerebellar cortex stained with serum from a patient with the stiff-man syndrome that contained glutamic acid decarboxylase 
antibodies shows only a few immunoreactive synapses, corresponding to aminobutyric acid-ergic synapses. These include synapses 
made by basket-cell axons around the axon hillocks of Purkinje cells (arrow). 
In Panel D, Panel E, and Panel F, adjacent sections of cerebellar cortex stained with serum samples from Patients 1, 2, and 3, 
respectively, have identical patterns of immunoreactivity. This pattern is very similar to that produced by rabbit antibodies directed 
against a nerve-terminal marker, synapsin I, as shown in Panel G. 
In Panel H and Panel I, adjacent sections of deep cerebellar nuclei stained with serum samples from Patients 1 and 3, respectively, 
show localized immunoreactivity in the cytoplasm of neuronal perikarya (P) and dendrites as well as in the nerve terminals that form 
synapses at their surfaces (arrows). Double-immunofluorescence labeling of a brain-stem section with serum from Patient 3 (Panel J) 
and antibodies directed against synaptophysin (Panel K), a synaptic-vesicle marker, shows nerve terminals filled with synaptic vesicles 
(white puncta). The profiles of neuronal perikarya and dendrites (arrows) are apparent. The scale bar measures 0.25 mm in Panel A, 25 
microm in Panel B and Panel C, 50 microm in Panels D, E, F, and G, and 25 microm in Panels H, I, J, and K. (Reprinted with permission 
from F. Folli et al, Autoantibodies to a 128 kd protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 
1993; 328: 546-551. Copyright 1993 Massachusetts Medical Society. All rights reserved). 
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